AGIX - As I postulated, AGIX bears watching. The results for the just announced ANDES trial indicate that there is probably still a liver tox issue at the lower doses.
BUT - they also may have found a screen for the patients who are likely to develop the liver tox. I would want to see details before getting on board conceptually - but the management team is better than the average biotech team so there is some chance they have a real screen. In which case this could be a blockbuster since it also has hard cardiac data.
Lots of ifs, but definitely interesting.
PS Bummer that it bounced so high on a result that was a fait accompli and I wasn't in - there was never really much doubt about the efficacy result after the interim indicated that their choice of trial sites wasn't suicidal. Apparently the market had still been in doubt - or maybe it is the new possibility of a screen that caused the bounce - just plain odd.
PPS Note on trial sites - as predicted, the Eastern Europe trial site was a bust. It was the other locations (e.g. India and S. Africa) that kept the trial working. Good info going forward.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.